Detecting drug use involving barbiturates, cocaine, and tetrahydrocannabinol
This test is not intended for use in employment-related testing.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
BARBU | Barbiturates Confirmation, U | Yes | No |
COKEU | Cocaine and metabolite Conf, U | Yes | No |
THCU | Carboxy-THC Confirmation, U | Yes | No |
Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol. Positives are confirmed and quantitated by definitive methods (gas chromatography-mass spectrometry for barbiturates, cocaine and metabolites, and tetrahydrocannabinol metabolite) at an additional charge.
Only orderable as part of profile. For more information see CSMPU / Controlled Substance Monitoring Panel, Random, Urine.
Immunoassay
Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol. Positives are confirmed and quantitated by definitive methods (gas chromatography-mass spectrometry for barbiturates, cocaine and metabolites, and tetrahydrocannabinol metabolite) at an additional charge.
Urine
The test does not screen for drug classes other than those listed above.
Only orderable as part of profile. For more information see CSMPU / Controlled Substance Monitoring Panel, Random, Urine.
Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative
20 mL
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 14 days | |
Frozen | 14 days | ||
Ambient | 72 hours |
Detecting drug use involving barbiturates, cocaine, and tetrahydrocannabinol
This test is not intended for use in employment-related testing.
Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol. Positives are confirmed and quantitated by definitive methods (gas chromatography-mass spectrometry for barbiturates, cocaine and metabolites, and tetrahydrocannabinol metabolite) at an additional charge.
This test uses the simple screening technique that involves immunologic testing for drugs by class. All positive immunoassay screening results are confirmed by gas chromatography-mass spectrometry (GC-MS) and quantitated before a positive result is reported.
This assay was designed to test for and confirm by GC-MS the following:
-Barbiturates
-Cocaine
-Tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.
Only orderable as part of profile. For more information see CSMPU / Controlled Substance Monitoring Panel, Random, Urine.
Negative
Screening cutoff concentrations:
Barbiturates: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past. See individual tests (eg, COKEU / Cocaine and Metabolite Confirmation, Random, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing.
No significant cautionary statements
1. Physicians' Desk Reference: 60th ed. Medical Economics Company; 2006
2. Bruntman LL, Lazo JS, Parker KL, eds: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006
3. Langman LJ, Bechtel L, Meier BM, Holstege CP: Clinical toxicology In: Rifai N, Horwath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:832-887
4. Jannetto PJ, Bratanow NC, Clark WA, et al: Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018 Jan 1;2(4):489-526
The barbiturate, cocaine metabolite, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: Roche Barbiturates. Roche Diagnostics; 11/2017, Cannabinoids. Roche Diagnostics; 11/2017, Cocaine. Roche Diagnostics; 11/2017)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
80307
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
PNRCH | Drug Immunoassay Panel, U | 87428-9 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
2574 | Barbiturates | 70155-7 |
21652 | Cocaine | 19359-9 |
2664 | Tetrahydrocannabinol | 19415-9 |